Neurocognitive research has focused on monoaminergic influences over broad behavior patterns. For example, dopamine (DA) generally facilitates informational transfer within limbic and cortical networks to promote reward-seeking behavior. Specifically, DA activity in prefrontal cortex modulates the ability for nonhuman primates and humans to perform spatial working memory tasks. Serotonin (5HT) constrains the activity of DA, resulting in an opposing relationship between DA and 5HT with respect to emotional and motor behaviors. A role for 5HT in constraining prefrontally guided spatial working memory (WM) processes in humans has not been empirically demonstrated but is a logical avenue for study if these principles of neurotransmitter activity hold within cortical networks. In this study, normal humans completed a visuospatial WM task under pharmacological challenge with (i) bromocriptine, a DA agonist and (ii) fenfluramine, a serotonin agonist, in a double-blind, repeated-measures, placebo-controlled design. Findings indicate that bromocriptine facilitated spatial delayed, but not immediate, memory performance. Fenfluramine resulted in impaired delayed spatial memory. These effects were not due to nonspecific arousal, attentional, sensorimotor or perceptual changes. These findings suggest that monoaminergic neurotransmitters (DA and 5HT) may interact within cortical networks to modulate the expression of specific cognitive behaviors, particularly effortful processes associated with goal-directed activity.
Introduction
In this report, we examine the modulatory roles of two monoaminergic neurotransmitters, dopamine (DA) and serotonin (5HT), with respect to working memory (WM) functions orchestrated by human prefrontal cortex (PFC). Centrally active neurochemicals have been investigated in terms of their inhibitory or excitatory effects on postsynaptic cells and/or their inhibitory or excitatory effects on specific behaviors (Spoont, 1992) . For example, DA appears generally to inhibit the activity of postsynaptic target cells but to facilitate the behavioral processes mediated by brain structures that are DA-innervated. Examples of behaviors facilitated by functional increases in DA activity include incentive-reward motivation, locomotor initiation and emotional response facilitation (Collins and Depue, 1992; P.F. Collins, unpublished) , all mediated through DA activity in the basolateral limbic forebrain. A role for DA in facilitating cognitive functions, particularly those guided by PFC, is also apparent (Beninger, 1983; Oades, 1985; Goldman-Rakic, 1987; Luciana et al., 1992) . Oades (1985) suggests a mechanism of DA facilitation, one whereby DA promotes the likelihood of switching between alternative sources of information both within and between neural circuits, allowing for modifications in the temporal characteristics of an ongoing informationprocessing sequence. This function has been defined with respect to cognitive functions as one of signal-to-noise enhancement (Sawaguchi et al., 1988 (Sawaguchi et al., , 1990a Servan-Schreiber, 1992, 1993) . DA enhances the incoming neural signal relative to background 'noise' or interference, thus creating a neural environment in which heightened DA activity promotes the firing frequency of innervated neurons.
The threshhold of DA's behavioral facilitation appears to depend not only upon 'trait' factors related to dopaminergic transmission, such as the number of midbrain DA cell bodies or receptors in target structures (Fink and Reis, 1981) but also upon other neuromodulators that provide regulatory inf luences over DA activity. One example of a neuromodulator that regulates DA activity is 5HT. Like DA, 5HT innervates widespread cortical and subcortical brain regions including the limbic forebrain, basal ganglia, frontal cortices and hypothalamic nuclei (Dahlstrom and Fuxe, 1964) . 5HT afferents are particularly prominent in the thalamus and sensory cortices, consistent with a prominent role for 5HT in modulating the f low of sensory information from the peripher y to neocortex (Morrison et al., 1984; Azmitia and Gannon, 1986) . Behavioral studies have demonstrated that 5HT provides tonic inhibition of DA's facilitatory effects with respect to a host of behaviors (Depue and Spoont, 1986; Soubrie, 1986; Spoont, 1992) . For example, hyperlocomotion (mediated through DA activity in the nucleus accumbens) is observed in rats following either increased DA transmission or decreased 5HT transmission, and reaches extreme levels when both neurochemical manipulations are employed (Grabowska, 1974; Gerson and Baldessarini, 1980; Jenner et al., 1983; Howell et al., 1997) . The same is true for other behavioral processes including DA-enhanced exploratory behavior (Gately et al., 1985) , intracranial self-stimulation (Leccese and Lyness, 1984; Nakahara et al., 1989) and responses to conditioned incentive cues (Leone et al., 1983; Hodges and Green, 1984) . Neurophysiologically, these findings are supported by evidence that receptors for DA and 5HT are present and overlapping in both limbic and cortical brain regions (Goldman-Rakic et al., 1990) . Moreover, specific interactions between prefrontal and limbic serotonergic receptor systems in modulating the ascending A10 DA pathways have been demonstrated (Hagan et al., 1993; Wang et al., 1995) .
Whether this opposing modulatory relation between DA and 5HT holds with respect to cognitive, as well as limbic and striatal, functions has not been studied extensively to date, but is important in understanding neuromodulatory inf luences within large-scale neurocognitive networks (Goldman-Rakic, 1988; Mesulam, 1993) . For example, the experimental manipulation of DA transmission in the dorsolateral prefrontal cortex (DLPFC) of nonhuman primates affects performance on prefrontally guided spatial WM processes (Goldman-Rakic, 1987; Sawaguchi and Goldman-Rakic, 1991) .
Working memory refers to processes that allow responserelevant information to be maintained or held 'on-line' for brief intervals and later used to guide behavioral actions (Baddeley, 1992; Goldman-Rakic, 1987 . In spatial WM paradigms, this information consists of parameters that define an object's location in extrapersonal space. Single-unit recordings from the DLPFC have identified several subtypes of task-related neurons during spatial WM performance which differentially increase in firing rate during the initial presentation of a stimulus cue, during the delay period, and spanning the interval between the temporal delay and the response initiation periods (Fuster and Alexander, 1971; Kojima and Goldman-Rakic, 1982; Funahashi et al., 1989) . Neurotoxic (6-hydroxydopamine) lesions of the PFC's dorsolateral convexity have produced impaired spatial delayed alternation performance in rhesus monkeys that was reversed by DA agonists (Brozoski et al., 1979) . Additionally, DA enhances PFC neuronal activity associated with the sequence of WM processes, including cellular responses to the spatial cue, the delay, and/or memory-guided response initiation (Sawaguchi et al., 1988 (Sawaguchi et al., , 1990a . Pharmacological blockade of DA receptors in monkeys results in reversible decrements in accuracy and latency of an oculomotor DR task (Sawaguchi and Goldman-Rakic, 1991) . Furthermore, Williams and Goldman-Rakic (1995) have demonstrated through the use of iontophoretic injections of D1 and D2 receptor antagonists into the nonhuman primate PFC that dopamine's facilitatory effects on the cellular processes that support WM are dose dependent. The D1 receptor system appears to specifically generate delay-related cellular activity, but only when stimulated at an optimal level. The role of the D2 system appears to be more complex, involving nonspecific regulation of task-relevant cellular activity. A lterations in the D2 receptor system also appear to contribute to the cognitive decline associated with normal aging (Arnsten et al., 1995) .
Human studies are consistent with these findings. Deficient spatial WM performance has been reported in humans with schizophrenia, an illness in which abnormalities of prefrontal DA activity have been proposed (Park and Holtzmann, 1994; Wong et al., 1986) , and connectionist modeling that includes a parameter to represent DA activity in cortical circuits accurately accounts for the types of cognitive deficits displayed by schizophrenics as they perfom WM tasks Ser van-Schreiber, 1992, 1993) . Relative to normal controls, individuals with Parkinson's disease demonstrate cognitive deficits on prefrontal tasks as well as decreased activation of prefrontal circuits during self-generated motor movements in a WM task (Gotham et al., 1988; Levin et al., 1989; Jahanshahi et al., 1995) . Finally, pharmacological activation of D2 DA receptors in normal humans has been demonstrated to facilitate WM in a visuomotor spatial WM task (Luciana et al., 1992) . The current study was designed to replicate this latter finding in a larger sample of normal subjects (Luciana and Collins, 1997) and to expand the research beyond a single-transmitter hypothesis. In particular, we were interested in delineating distinct functional principles of activity for DA and 5HT in cognition by examining their roles in spatial WM performance.
Serotonin's role in learning and memory is among the least understood of the monoaminergic neurotransmitters (Gold and Zornetzer, 1983; Ogren, 1985; Wolkowitz et al., 1985) , largely because empirical findings vary depending upon the method by which 5HT is manipulated, the extent of 5HT depletion or enhancement, and the nature of the behavioral task employed (Cole et al., 1994; Lalonde and Vikis-Freibergs, 1985) . Consistent with a proposed role for 5HT in inhibitory processes (Gray, 1982) , Fibiger et al. (1978) were among the first to report that electrical stimulation of the midbrain dorsal raphe (the source of serotonergic projections to the cortex and striatum) disrupted animals' acquisition of a passive avoidance task. It has since been demonstrated that intracerebral injections of 5HT impair post-training retention of avoidance learning (Lalonde and Vikis-Freibergs, 1985) and that administration of selective 5HT receptor agonists impairs a range of cognitive abilitites, including passive avoidance , memory of fear conditioning (Quartermaine et al., 1993) , spatial learning , operant learning in a delayed-matchto-sample task (Cole et al., 1994) and, most relevant to the current study, WM on a radial arm maze task (Winter and Petti, 1987) . Furthermore, intrahippocampal implantation of serotonergic ner ve grafts impaired rats' performance on a spatial learning task (Ramirez et al., 1989) . Administration of 5-HT receptor antagonists, such as ondansetron, has been noted to improve rats' cognitive performance in a water maze (Fontana et al., 1995) and to improve other abilities such as avoidance, spatial and visual learning (McEntee and Mair, 1980; Normile, 1986, 1988; Barnes et al., 1990; Domeney et al., 1991; Carey et al., 1992; McEntee and Crook, 1991) .
Whether these findings can be applied to humans has not been extensively studied, although cognitive deficits have been noted in human volunteers after receiving acute doses of 5-HT agonists (Grasby et al., 1992 ; see Robbins, 1997 , for a brief review) and in psychiatric patients receiving selective serotonergic reuptake inhibitors (Bartfai et al., 1991; Sofuoglu and DeBattista, 1996) . Accordingly, we examined neuromodulatory inf luences on spatial WM in normal humans using systemic administration of fenf luramine (Pondimin), a 5HT agonist, and bromocriptine (Parlodel), a DA agonist. We have previously reported on the specific agonistic-antagonistic effects of bromocriptine and haloperidol on spatial memory task performance (Luciana and Collins, 1997) . A subsample of the participants who contributed data to our earlier report (n = 38 of 50 subjects) were also administered fenf luramine, and they are the subjects of the current study.
Materials and Methods

Subjects
Twenty-four males and 14 females, aged 19-35 years (mean ± SD = 25.33 ± 4.38) gave informed consent after the nature and possible consequences of participation were explained. Subjects were psychiatrically normal, as determined by structured interviews (Spitzer et al., 1990) administered by the first two authors. Exclusions for pregnancy, oral contraceptive use during the previous 4 months, prescribed medication during the previous 6 months, substance abuse, menstrual irregularities, endocrinopathies, neurological disease or other relevant clinical conditions were applied. All participants were examined by a physician prior to participation.
Psychopharmacological Manipulations
Subjects were studied in a double-blind crossover repeated-measures design. All subjects received placebo (2.5 mg lactose), a 1.25 mg dose of bromocriptine and a 60 mg dose of fenf luramine, a serotonin agonist, during separate experimental sessions. Manipulation of the D2 DA system was primarily selected because of the role that these receptors are thought to play in a variety of motivational behaviors (Snyder and Peroutka, 1984; Oades, 1985; Depue and Iacono, 1989; Luciana et al., 1992) . (See Luciana et al., 1992; Depue et al., 1994; Luciana and Collins, 1997 , for complete rationales on the use of bromocriptine.) Fenf luramine's major clinical use is as an anorectic agent, similar in structure to amphetamine but without amphetamine's psychostimulant properties (Murphy et al., 1986) . The major 5HT agonistic properties of fenf luramine are due to its ability to promote a rapid release of 5HT from presynaptic terminals (Schwartz et al., 1989; Sabol et al., 1992) although it can also potentiate serotonergic function by inhibiting the reuptake of serotonin (Garratini et al., 1975) . Because fenf luramine is receptor nonspecific, it induces a generalized increase in 5HT neurotransmission throughout the central nervous system. The specificity of fenf luramine's activation of 5HT (but not catecholaminergic) systems has been supported by neurochemical and behavioral studies (Wood and Emmett-Oglesby, 1988; Maura et al., 1992; Brauer et al., 1996; Shoabib et al., 1997) .
In this study, validation of each drug's effects was ascertained by its inf luence on the secretion of the neurohormone prolactin (PRL), externally measured in blood serum. In humans, PRL secretion is reliably and markedly inhibited by bromocriptine in a dose-dependent fashion, with strong correlations between inhibition of PRL secretion and bromocriptine dose and serum concentration (Lieberman et al., 1989) .
Conversely, acute doses of fenf luramine lead to dose-dependent increases in serum PRL secretion in healthy human controls (Coccaro et al., 1990; Park et al., 1995) and in nonhuman primates (Shively et al., 1995) . Moreover, these effects are most significant when the oral dosage exceeds 60 mg. Fenf luramine-dependent increases in serum PRL are blocked by the 5HT angatonist metergoline and by the 5HT2 antagonist ritanserin, suggesting that fenf luramine's effects on PRL secretion are mediated through the 5HT2 receptor system. The 5HT2 receptor system receives projections from the dorsal raphe, which is also the source of serotonergic projections to frontal cortex (Spoont, 1994) .
Study Protocol
The protocol ran from 11.00 to 19.00 h, beginning with the insertion of an i.v. catheter into the participant's nondominant forearm. Identical drug capsules were orally ingested at 12.00 h. In order to provide an adequate washout period, experimental sessions were separated by at least 3 days (Gruen et al., 1978.; McClelland et al., 1990) . Subjects remained awake and recumbent throughout the protocol. They fasted from midnight the previous night until noon, with the exception of several glasses of 2% milk to prevent hunger and nausea. Subjects abstained from caffeine, nonprescription medications and alcohol for at least 24 h before testing and were asked to observe a low monoamine diet for 48 h prior to each visit. From 15.30 to 17.00 h during each experimental session, participants completed several computerized cognitive measures. These included a spatial WM task, a nonmnemonic spatial location task and a biletter cancellation vigilance task. These are each described in detail below.
Spatial Working Memory Task
Subjects were seated with sound-damping headphones and an adjustable chin-forehead rest with eyes 27 cm from a monochrome computer monitor. During each trial, subjects observed a central fixation point (a black '+', 0.63° × 0.63°) on the monitor for 3 s. Next, a visual cue (a black circle, 0.21°diameter) appeared in peripheral vision within a 360°c ircumference for 200 ms. After the occurrence of this visual cue, the cue and fixation point disappeared, and the screen blackened for delay intervals of 500, 4000 or 8000 ms. After the delay interval, the screen instantly lit, and the subject indicated the screen location of the cue with a fine-pointed lightpen, an input device which activates the monitor to be touch-sensitive to it (FTG Data Systems, Inc.). Forty-eight trials (16 500, 16 4000 and 16 8000 ms delays), with a 2.0 s intertrial inter val, were completed with delays randomly interspersed and cue locations randomized over trials. Visual cues were presented at four different locations in each of four quadrants for the three delay conditions. Visual cue eccentricities were 10°, in order to minimize the use of edge or center cues and to ensure that cues did not fall within each subject's blind spot. Locations of 0°, 90°, 180°and 270°were not included because of the possibility of spatial referencing to exact vertical and horizontal positions. Cue location was randomized over trials so that the subject could not predict where the cue would appear on any given trial. This design was identical to that used in a preliminary study of this research (Luciana et al., 1992) and to that described in an additional report (Luciana and Collins, 1997) . That this task is a reliable measure of WM is demonstrated by the finding of significantly decreased accuracy of subjects' performance on 500 ms delay versus no-delay trials under placebo conditions and by continuous decrements in performance accuracy as the delay interval is increased from 500 ms to 8 s (Luciana et al., 1992; Luciana and Collins, 1997) .
Nonmnemonic Spatial Location Control Task
A second visuospatial response task was added to this first measure in order to determine more precisely that observed effects were not due to drug effects on basic perceptual and/or sensorimotor processes. Prior to completing the delayed response task described above, each subject completed a nonmnemonic spatial location task during which (s)he completed 16 stimulus trials (one at each stimulus location described above), where the initial stimulus ( a black '*') remained on screen after its initial appearance. Subjects were instructed simply to touch the stimulus dot with the lightpen. Accuracy and latency to respond were recorded.
Scoring Method
Subjects' errors in locating the visual cue in both the visuospatial WM and nonmnemonic spatial location control task were scored as a composite function of the horizontal and vertical distance (in mm) from actual cue location. For each trial, composite error scores was computed by Pythagorean theorem [(horizontal error distance) 2 + (vertical error distance) 2 = (composite error distance score) 2 ]. Composite error scores were summed across each of the 16 trials within the four (no delay, 500, 4000 and 8000 ms) delay intervals and averaged to yield four scores for each subject for each drug condition (placebo, bromocriptine and fenf luramine,). Subjects were not given feedback as to the accuracy of their performance.
Biletter Cancellation Task
To assess each drug's effect on the maintenance of nonspecific attentional, arousal and motor processes involved in a targeted visual search, a biletter cancellation task (Lezak, 1983 ) was administered. This task is a paper-and-pencil measure in which the subject views lined arrays of letters on an 8.5 × 11 inch sheet of paper. The letters are presented in upper case and organized in six horizontal rows of 52 letters each. The subject is instructed to draw a line through all occurrences of two target letters (Es and Cs) as quickly, but as accurately as possible. Time to completion is recorded but is not experimentally restricted. Number of omission and commision errors (unmarked target letters and incorrectly marked nontarget letters respectively) and the time to completion were tabulated for each drug condition.
The order of cognitive task administration was identical for each subject on each study day. The nonmnemonic spatial location task was administered first, followed by the spatial WM and biletter cancellation tasks.
Assessment of Prolactin Secretion
Assessment Procedures
Pre-drug samples for baseline serum PRL were obtained at 11.45 and 11.55 h and averaged; 13 post-drug samples were obtained every 30 min from 13.00 to 19.00 h. PRL assessment was limited to days 2-10 (early to middle follicular phase) of females' menstrual cycles. Blood samples were spun down immediately, and serum samples were assayed in duplicate within 2 days at the University of Minnesota Hospital Laboratory by use of double-antibody radioimmunoassay.
Blood Pressure Assessment
Standing blood pressure was recorded at the start and end of each study day. To record global changes in arousal levels, recumbent systolic and diastolic blood pressures and pulse rates were measured by a registered nurse hourly throughout each day.
Results
Statistical Analyses
Data were analyzed by univariate repeated-measures analyses of variance (BMDP version 7.0, modules 2V and 4V) and paired t-tests (BMDP module 3D). Alpha levels below 0.05 were viewed as statistically significant.
Exclusions
Medical records detailing the sequence of events during each experimental session were blindly reviewed prior to data analysis by the first two authors (M.L. and P.C.), who reached consensus as to the validity of cognitive data collected within each experimental session. Circumstances potentially affecting the quality of collected data were noted. Subjects who experienced significant adverse reactions under any drug condition were excluded from data analyses within that drug condition. Adverse effects were typically related to bromocriptine administration (n = 10 subjects), and most often included sedation, nausea, dizziness, light-headedness due to a fall in systolic or diastolic blood pressure and/or vomiting during the time of cognitive task administration. The 38 subjects (24 males and 14 females) who contributed data to this report completed both the bromocriptine and fenf luramine protocols without adverse reactions.
Drug Effects on Prolactin Secretion (Figure 1)
Drug effect values for individual subjects within each placebodrug comparison were computed. The average baseline PRL value on each day of study was first computed by averaging the 11.45 and 11.55 h pre-drug specimen values for each experimental session. To control for variations in baseline, each PRL value in a subject's placebo, bromocriptine and fenf luramine series was expressed as a change from its respective average baseline value. Thus, each series was represented by 13 PRL baseline-corrected values. Five of these values (15.30, 16.00, 16.30, 17 .00 and 17.30 h) were summed to represent, for each experimental session, the total PRL effect during the time of cognitive task administration. Comparison of these values on placebo versus bromocriptine indicated a marked inhibition of PRL by bromocriptine relative to placebo during the task administration interval [t(37) = -5.52, P = 0.000]. Conversely, comparisons of placebo and fenf luramine values indicate an increase in PRL secretion during the task administration interval [t(37) = 8.06, P = 0.000], indicating that fenf luramine was physiologically active during the time of cognitive task administration. Furthermore, the mean time of the maximum effects on PRL secretion by each drug (∼17.00-17.30 h) occurred during the task administration interval with no return toward baseline values observed within this time period.
Drug Effects on Accuracy of Visuospatial Delayed Response Performance (Figure 2)
Means and standard deviations for accuracy and latency of spatial delayed response performance within each drug and delay (500, 4000, 8000 ms) condition are represented in Table 1 . A repeated-measures ANOVA on averaged error scores over trials on three delays (500, 4000, 8000 ms) and three drug conditions (placebo versus bromocriptine versus fenf luramine) indicated a main effect of drug [F(2,74) = 4.54, P < 0.05], a main effect of delay [F(2,74) = 95.73, P < 0.000], and a significant drug × delay interaction [F(4,148) = 5.20, P < 0.001]. A priori linear contrasts were done to assess the effects of bromocriptine versus fenf luramine on performance accuracy. As compared to placebo, there was a marginal main effect of bromocriptine [F(1,37) = 2.81, P = 0.10] as well as a significant drug × delay interaction [F(2,74) = 3,31, P < 0.05]. For the fenf luramine versus placebo comparison, there was no significant main effect of drug, but there was also a significant drug × delay interaction [F(2,74) = 3.45, P < 0.05].
Similar contrasts were performed to compare performance on short delay (4000 ms) and long delay (8000 ms) drug trials relative to the 500 ms delay under each drug condition. For short-delay trials (4000 versus 500 ms), there was no significant drug × delay interaction for bromocriptine/placebo comparisons [F(1,37) = 2.79, NS] or for fenf luramine/placebo comparisons [F(1,37) = 0.09, NS]. For long delay trials (8000 versus 500 ms), there were significant drug × delay interactions relative to placebo for both bromocriptine [F(1,37) = 6.04, P < 0.05] and fenf luramine [F(1,37) = 6.30, P < 0.05]. These drug effects, represented in Figure 2 , indicate that accuracy of performance on 4000 ms trials was not manipulated by either bromocriptine or fenf luramine administration. The finding of a significant drug × delay interaction in the long delay condition (8000 versus 500 ms) indicated inhibition of 8000 ms delayed memory performance by fenf luramine and facilitation of 8000 ms delayed memory performance by bromocriptine. 
Drug Effects on Latency of Visuospatial Delayed
Drug Effects on Basic Sensorimotor and Attentional Processes
Nonmnemonic Spatial Location Performance (see Table 1 ) Drug effects on basic sensorimotor and perceptual abilities were examined. Subjects' errors in touching a stimulus dot with the lightpen device when the dot remained on screen were examined. Means and standard deviations for accuracy scores and response latencies are represented in Table 1 . There was no effect of drug condition (bromocriptine or fenf luramine, relative to placebo) on average performance acuracy [F(1,31) = 0.31, NS] or response latency [F(2,62) = 0.84, NS] for this group of subjects.
Biletter cancellation task (Table 2)
A repeated-measures ANOVA comparing the total error score across drug conditions yielded no main effect of drug [F(2,72) = 0.01, NS]. A similar analysis on the times to completion across drug conditions yielded no effect of drug [F(2,72) = 0.30, NS]. Means and standard deviations representing task performance within each drug condition are presented in Table 2 . 
Moderators of Cognitive Performance
Error scores and response latencies under placebo conditions were not significantly associated with age (rs = 0.01-0.21). Similarly, the effects of bromocriptine and fenf luramine on task performance were unrelated to age. There were no main effects of gender or interactions between drug condition and gender on task performance. Finally, there were no main effects of visit number or interactions between drug condition and visit number for performance on the delayed response task.
Drug Effects on Blood Pressure and Pulse Rate (Figure 4)
The effects of each drug on systolic and diastolic blood pressures were evaluated in a manner similar to PRL secretion. Blood pressure was recorded hourly from 12.00 to 19.00 h while subjects were in a recumbent position. Drug effect values for individual subjects within each placebo-drug comparison were computed. The baseline blood pressure value on each day of study was assessed at 12.00 h, and consisted of recordings of both systolic and diastolic blood pressures. To control for variations in baseline across separate study days, each subsequent blood pressure value in a subject's placebo, bromocriptine and fenf luramine series was expressed as a change from its respective baseline value. Thus, each series was represented by seven baseline-corrected values. Three of these values (15.00, 16.00, 17.00 h) were summed to represent, for each experimental session, the total blood pressure effect during the time of cognitive task administration. From 15.00 to 17.00 h there was a significant difference in baseline-corrected systolic blood pressure on placebo versus bromocriptine [t(37) = -4.55, P < 0.001] but not between placebo and fenf luramine [t(37) = 0.45. NS]. Bromocriptine resulted in a systematic decrease in systolic blood pressure over time. Diastolic blood pressure was similarly evaluated, yielding a significant effects of bromocriptine [t(37) = -1.99, P = 0.05] but no significant effect of fenf luramine [t (37) 
Discussion
Spatial WM processes, at delays exceeding 4000 ms, appear to have been facilitated in the same group of subjects by bromocriptine and impaired by fenf luramine. Neither bromocriptine nor fenf luramine affected task components that were unrelated to the delay manipulation such as attentional, sensory or psychomotor processes engaged in attending to the trial sequence and formulating a response as indexed by performance on the biletter cancellation task and by nonmnemonic spatial location performance. Assessment of autonomic indices of arousal (blood pressure and pulse rate) indicated that bromocriptine resulted in a significant decrease in blood pressure during the task administration inter val. Pulse rate was not affected. Relative to placebo values, fenf luramine administration did not result in significant blood pressure or pulse rate changes.
The pattern of results supports several general conclusions with respect to potential dopaminergic-serotonergic interactions in the modulation of specific cognitive behaviors. Although we acknowledge that our effect sizes are small, we have progressively demonstrated and replicated our finding of facilitated spatial WM in normal humans by increased DA transmission and impairment by decreased DA transmission (Luciana et al., 1992; Luciana and Collins, 1997) . These data parallel findings in nonhuman primates with respect to modulation of spatial WM functions following manipulations of DA transmission in DLPFC. The suggestion based on the primate literature is that DA acts on a neuronal level to enhance the stimulus signal across the temporal delay inter val relative to background noise or interference (Sawaguchi et al., 1988 (Sawaguchi et al., , 1990a . Our findings are consistent with this hypothesis.
In this study, increased 5HT transmission impaired spatial WM, consistent with 5HT's opposing modulatory inf luence relative to DA on other behaviors. That is, functional increases of 5HT, as achieved by a single acute dose of fenf luramine, appear to have constrained the general f low of information that underlies successful peformance on this task. A more direct test of DA/5HT interactions would be accomplished by administering doses of DA and 5HT agonists simultaneously to the same group of subjects. However, if DA is endogenously activated during spatial memory performance, as would be presumed from the animal literature, which emphasizes the importance of catecholamines in the modulation of WM (Goldman-Rakic, 1987; Sawaguchi and Goldman-Rakic, 1991) , then 5HT appears to have countered the effects of task-related DA enhancement, as has been demonstrated with other forms of behavior, including 5HT's attenuation of amphetamine-induced hyperlocomotion. Moreover, the effects of fenf luramine on specific parameters of WM performance exactly parallel what is seen when DA is exogenously activated using bromocriptine, despite the fact that an exact parametric correpondence between the doses of each drug used for individual subjects was not attempted.
Given the preponderance of 5HT in sensory pathways and the presence of DA in basal ganglia circuits, it is significant that the observed changes in cognitive task performance did not appear to be secondary to changes in basic sensorimotor, attentional or global arousal processes. Neither bromocriptine nor fenf luramine exerted an inf luence on task response latencies, on the ability to simply locate a stimulus dot under nonmnemonic conditions nor on a speeded targeted visual search task. A lthough our findings suggest that bromocriptine caused a decrease in autonomic arousal, fenf luramine administration did not result in a corresponding increase. Moreover, if changes in arousal are mediating cognitive performance, the effects are not equivalent across tasks or with respect to performance parameters within a task. Hence, we conclude that these data provide support for the interpretation that the observed changes in spatial WM performance are due, not to basic motor, mnemonic or sensory alterations, but to each drug's effects on processes that are associated with the temporal integration of the sensory cue with the desired response.
Neither bromocriptine nor fenf luramine exerted inf luences on WM task performance until the delay interval exceeded 4 s. While it may be that longer delay intervals are necessary to tax executive processes that support WM in normal adult humans, applications of DA or its antagonists directly into the principal sulcal region of nonhuman primates results in changes in task performance when temporal delay intervals are as short as 1 s (Sawaguchi and Goldman-Rakic, 1991) . The fact that performance accuracy was not altered, even subtly, at all delay intervals raises the question of whether short versus long delay intervals equivalently engage processes outside of memory that are important for optimal 'working with memory' performance. Robbins (1996) notes that when normal humans perform a self-ordered searching task involving spatial WM, they recruit an organized strategy to minimize the task's mnemonic demands. Moreover, although individuals with both frontal and temporal lobe lesions demonstrate mnemonic errors on the task, strategy use is significantly impaired in 70% of patients with lesions to the frontal, but not temporal, lobes of the brain (Owen et al., 1990 (Owen et al., , 1996 and correlates with the degree of mnemonic error in this group. Based on these findings, Robbins (1996) provides empirical support to suggest that deficient performance on spatial WM tasks involve two components: one that is purely mnemonic (highly dependent upon temporal lobe structures) and one that involves strategic use of memory to accomplish behavioral goals, dependent on an intact PFC. Our data support the view that monoaminergic neurotransmitters interact to modulate spatial WM performance through this latter, more 'effortful' task component, since neither bromocriptine nor fenf luramine affected purely mnemonic or psychomotor aspects of performance.
What types of effortful processes might contribute to accurate spatial WM performance in a delay-dependent manner? It seems reasonable to speculate that more difficult task items (e.g. those requiring mnemonic integration through increasingly long temporal delays) tax not only short-term memory processes, but also higher-order processes such as focused attention and inhibitor y control that are important for maintaining motivational resources over time, allowing for ongoing effort toward the achievement of specific goals (in this case, accuracy of manually guided task performance). The importance of effortful processes as mediators of frontal lobe task performance has been emphasized in several recent reports (Burgess and Shallice, 1996; Luciana and Nelson, 1997; Wheeler et al., 1997) .
Moreover, a specific role for serotonin in modulating motivational biases during cognitive task performance has been suggested (Steckler and Saghal, 1995) . With respect to DA, Williams and Goldman-Rakic (1995) suggest a precise role for the D1 receptor system in modulating the 'memory fields' of locally active neurons. Their research suggests that systemic administration of D1 receptor agonists, at optimal dose levels, would enhance mnemonic processes regardless of delay interval. In constrast, Williams and Goldman-Rakic (1995) found that iontophoretic administrations of D2 antagonists did not specifically alter the mnemonic fields of task-related neurons. This obser vation is consistent with the fact that the cortical distribution of D2 receptors is prominent in layers III and V, where information processing occurs through widespread corticocortical, corticostriatal and corticolimbic networks (see Luciana et al., 1992 , for a more complete discussion). Hence, the predicted effects of subtle manipulations of the D2 system on WM would not involve alterations in specific processes, but in those aspects of task performance that best ref lect the effortful integration of sensory, motor, mnemonic and motivational resources. Under pharmacological challenge conditions, it is likely that increasingly pronounced behavioral changes would be observable either with increased task demand (e.g. in the course of longer delay intervals, by increasing informational load within WM tasks, or under conditions of low motivation) or with more direct neurochemical manipulations.
Clinical Implications
Although distinct modulatory roles for DA and 5HT have gained increasing acceptance with respect to limbically mediated emotional and striatally mediated motor behaviors, the findings of this study suggest that complex cognitive functions, such as those organized within prefrontal cortical circuitr y, may fall under opposing modulatory inf luences of DA and 5HT similar to those obser ved in studies of simpler forms of behavioral responding in nonhuman primates. Under the most adaptive set of endogeneous conditions, the neurochemical balance between DA and 5HT could be inf luential in determining overall proficiency in similar cognitive tasks. These findings are important from a clinical perspective, since both DA and 5HT disruptions have been implicated in psychiatric disorders including schizophrenic psychosis (Kapur and Remington, 1996) , mood disorders (Depue and Iacono, 1989; Kramer, 1991) and disorders of impulse control (Coccaro et al., 1989) . Although current psychiatric treatment strategies tend to focus on manipulations of one transmitter system or the other (Kramer, 1991) , leading to single-transmitter theories of etiology of specific clinical disorders, it is likely that an understanding of the complex interactions among modulatory neurotransmitters may contribute to increasingly refined pharmacological treatments.
Whether this finding of impaired spatial WM by fenf luramine can be generalized to nonspatial forms of WM and replicated through the use of other psychopharmacological agents is a matter for continued research. Moreover, it is essential, from a clinical standpoint, to assess whether similar pharmacological effects would be evident in the course of chronic versus acute treatment with other 5HT agonists.
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